H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 75 Citations 19,391 400 World Ranking 823 National Ranking 23
Medicine D-index 97 Citations 36,768 700 World Ranking 4394 National Ranking 125

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Virus
  • Acquired immunodeficiency syndrome

Immunology, Internal medicine, Virology, Viral load and Acquired immunodeficiency syndrome are his primary areas of study. His research brings together the fields of Cerebrospinal fluid and Immunology. His Internal medicine study incorporates themes from Sida, Surgery and Pharmacology.

His Virology research includes themes of Chemokine, Peripheral blood mononuclear cell, Antibody and Antigen. His Viral load study integrates concerns from other disciplines, such as Raltegravir Potassium, Tolerability, Randomized controlled trial, Reverse-transcriptase inhibitor and Raltegravir. The study incorporates disciplines such as Seroconversion, Incidence and Risk factor in addition to Acquired immunodeficiency syndrome.

His most cited work include:

  • Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. (1123 citations)
  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection (610 citations)
  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. (557 citations)

What are the main themes of his work throughout his whole career to date?

Adriano Lazzarin spends much of his time researching Immunology, Internal medicine, Virology, Acquired immunodeficiency syndrome and Viral load. His study in Viral disease, Virus, Immunopathology, Immune system and Antibody are all subfields of Immunology. His Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Ritonavir.

His Virology study combines topics from a wide range of disciplines, such as Peripheral blood mononuclear cell and Genotype. His studies in Acquired immunodeficiency syndrome integrate themes in fields like Epidemiology, Incidence, Pediatrics and Seroconversion. Adriano Lazzarin usually deals with Regimen and limits it to topics linked to Pharmacology and Efavirenz.

He most often published in these fields:

  • Immunology (40.77%)
  • Internal medicine (39.41%)
  • Virology (34.57%)

What were the highlights of his more recent work (between 2011-2021)?

  • Internal medicine (39.41%)
  • Virology (34.57%)
  • Gastroenterology (15.12%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Virology, Gastroenterology, Viral load and Regimen. The various areas that Adriano Lazzarin examines in his Internal medicine study include Emtricitabine, Pharmacology and Ritonavir. His research in Virology intersects with topics in Immunology, Genotype and Antiretroviral therapy.

His Gastroenterology research is multidisciplinary, incorporating perspectives in Rilpivirine, Hepatitis C, Retrospective cohort study, Confidence interval and Lamivudine. His Viral load research integrates issues from Viremia and Surgery. Adriano Lazzarin has included themes like Tenofovir alafenamide, Protease inhibitor, Randomized controlled trial and Cohort in his Regimen study.

Between 2011 and 2021, his most popular works were:

  • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study (208 citations)
  • Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study (116 citations)
  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial (115 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Virus
  • Acquired immunodeficiency syndrome

Adriano Lazzarin focuses on Internal medicine, Viral load, Virology, Gastroenterology and Regimen. His Internal medicine research incorporates themes from Efavirenz, Pharmacology and Emtricitabine. His Viral load research includes elements of Interquartile range, Cross-sectional study, Viremia, Retrospective cohort study and Antiretroviral therapy.

His work deals with themes such as RNA, Raltegravir, Immunology and Genotype, which intersect with Virology. The concepts of his Gastroenterology study are interwoven with issues in Liver biopsy, Hepatitis C virus, Hepatitis C, Ritonavir and Coinfection. His studies deal with areas such as Tenofovir alafenamide, Discontinuation and Pediatrics as well as Regimen.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen.
The New England Journal of Medicine (2004)

1682 Citations

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron.
The New England Journal of Medicine (2008)

875 Citations

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes.
The New England Journal of Medicine (2003)

809 Citations

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard.
The Lancet (2009)

781 Citations

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell.
The Lancet (2007)

773 Citations

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson.
The Lancet (2007)

710 Citations

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper.
The Lancet (2007)

650 Citations

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh.
The New England Journal of Medicine (2008)

587 Citations

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin.
The Lancet (2011)

487 Citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley.
The Lancet (2006)

439 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Adriano Lazzarin

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 128

Andrew N. Phillips

Andrew N. Phillips

University College London

Publications: 124

Jens D. Lundgren

Jens D. Lundgren

Rigshospitalet

Publications: 121

Mark A. Wainberg

Mark A. Wainberg

McGill University

Publications: 117

David A. Cooper

David A. Cooper

Pfizer (United States)

Publications: 97

Andrea Antinori

Andrea Antinori

Catholic University of the Sacred Heart

Publications: 89

Dominique Costagliola

Dominique Costagliola

Université Paris Cité

Publications: 83

Antonella d'Arminio Monforte

Antonella d'Arminio Monforte

University of Milan

Publications: 82

Carlo Federico Perno

Carlo Federico Perno

University of Milan

Publications: 81

Christine Katlama

Christine Katlama

Université Paris Cité

Publications: 81

Caroline Sabin

Caroline Sabin

University College London

Publications: 80

Paul E. Sax

Paul E. Sax

Brigham and Women's Hospital

Publications: 80

Pere Domingo

Pere Domingo

Autonomous University of Barcelona

Publications: 80

José M. Gatell

José M. Gatell

University of Barcelona

Publications: 77

David C. Montefiori

David C. Montefiori

Duke University

Publications: 74

Guido Poli

Guido Poli

Vita-Salute San Raffaele University

Publications: 73

Something went wrong. Please try again later.